Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma,Pediatric Blood & Cancer

当前位置： X-MOL 学术 › Pediatr. Blood Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma
Pediatric Blood & Cancer ( IF 2.4 ) Pub Date : 2021-09-07 , DOI: 10.1002/pbc.29319
Jane Koo ₁ , Ashley Teusink-Cross ₂ , Stella M Davies ₁ , Sonata Jodele ₁ , Christopher E Dandoy ₁

Affiliation

High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is an established treatment for pediatric and young adult patients with solid tumors and lymphomas. Plerixafor is a CXC chemokine receptor type 4 (CXCR4) antagonist that can be used with granulocyte colony stimulating factor (G-CSF) to amplify the mobilization of hematopoietic stem cells (HSCs).

中文翻译：

单中心结果报告改善了患有实体瘤和淋巴瘤的儿科和年轻成人患者的造血干细胞动员成功率

自体造血干细胞移植（auto-HSCT）的大剂量化疗是治疗实体瘤和淋巴瘤的儿童和年轻成人患者的既定疗法。Plerixafor 是一种 CXC 趋化因子受体 4 型 (CXCR4) 拮抗剂，可与粒细胞集落刺激因子 (G-CSF) 一起使用以放大造血干细胞 (HSC) 的动员。

更新日期：2021-09-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11